European Medicines Agency recommends granting marketing authorization for pertuzumab

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product pertuzumab (Perjeta), 420 mg, concentrate for solution for infusion intended for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. The applicant for this medicinal product is Roche Registration Ltd. Read more here.